cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis
Authors
Keywords
-
Journal
Nature Cancer
Volume 3, Issue 11, Pages 1284-1299
Publisher
Springer Science and Business Media LLC
Online
2022-11-23
DOI
10.1038/s43018-022-00462-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence
- (2021) Eugen Dhimolea et al. CANCER CELL
- Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy
- (2021) Sumaiyah K. Rehman et al. CELL
- A Malignant Case of Arrested Development: Cancer Cell Dormancy Mimics Embryonic Diapause
- (2021) Yu-Hsuan Lin et al. CANCER CELL
- Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
- (2021) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Senolytics for Cancer Therapy: Is All that Glitters Really Gold?
- (2021) Valerie J. Carpenter et al. Cancers
- Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers
- (2021) Antonella Montinaro et al. CELL DEATH AND DIFFERENTIATION
- The Cancer SENESCopedia: A delineation of cancer cell senescence
- (2021) Fleur Jochems et al. Cell Reports
- Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist
- (2021) Abel Soto-Gamez et al. CANCER LETTERS
- BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer
- (2020) Ashkan Shahbandi et al. CELL DEATH AND DIFFERENTIATION
- Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
- (2019) Owen A. O’Connor et al. JOURNAL OF CLINICAL ONCOLOGY
- Inducing and exploiting vulnerabilities for the treatment of liver cancer
- (2019) Cun Wang et al. NATURE
- An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential
- (2018) Liqin Wang et al. CELL
- A versatile drug delivery system targeting senescent cells
- (2018) Daniel Muñoz‐Espín et al. EMBO Molecular Medicine
- NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
- (2018) Marcus Ruscetti et al. SCIENCE
- A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies
- (2017) Ankit C. Borisa et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer
- (2017) Liqin Wang et al. Cell Reports
- Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression
- (2016) Tobias Eggert et al. CANCER CELL
- CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes
- (2016) Bastiaan Evers et al. NATURE BIOTECHNOLOGY
- Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
- (2016) John G Doench et al. NATURE BIOTECHNOLOGY
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse
- (2016) Marco Demaria et al. Cancer Discovery
- Agonists of the TRAIL Death Receptor DR5 Sensitize Intestinal Stem Cells to Chemotherapy-Induced Cell Death and Trigger Gastrointestinal Toxicity
- (2015) N. K. Finnberg et al. CANCER RESEARCH
- Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models
- (2015) Y. Liu et al. CLINICAL CANCER RESEARCH
- Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
- (2015) Jianhui Chang et al. NATURE MEDICINE
- ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R–mediated apoptosis
- (2014) Thomas Condamine et al. JOURNAL OF CLINICAL INVESTIGATION
- Rational design of highly active sgRNAs for CRISPR-Cas9–mediated gene inactivation
- (2014) John G Doench et al. NATURE BIOTECHNOLOGY
- Improved vectors and genome-wide libraries for CRISPR screening
- (2014) Neville E Sanjana et al. NATURE METHODS
- Lentiviral Delivery of RNAi for In Vivo Lineage-Specific Modulation of Gene Expression in Mouse Lung Macrophages
- (2013) Andrew A Wilson et al. MOLECULAR THERAPY
- Synthetic lethal metabolic targeting of cellular senescence in cancer therapy
- (2013) Jan R. Dörr et al. NATURE
- Screening for modulators of cisplatin sensitivity: Unbiased screens reveal common themes
- (2011) Jeroen H. Nijwening et al. CELL CYCLE
- The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression
- (2010) Jean-Philippe Coppé et al. Annual Review of Pathology-Mechanisms of Disease
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network
- (2008) Thomas Kuilman et al. CELL
- Critical pathways in cellular senescence and immortalization revealed by gene expression profiling
- (2008) A L Fridman et al. ONCOGENE
- Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease
- (2008) K. Takeda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now